Autoimmune diseases involve self-tissue destruction by T-cells and antibodies due to lack of self-tolerance. The incidence of autoimmune disease is increasing. Autoimmune diseases can affect almost any part of the body. Antibody therapy is used in numerous diseases including rheumatoid arthritis, multiple sclerosis, lupus, myasthenia gravis, immune thrombocytopenia and skin blistering diseases.
Efgartigimod is a first-in-class investigational antibody fragment being evaluated for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G, or IgG, where a severe unmet medical need exists. Efgartigimod is thought to degrade circulating disease-causing autoimmune antibodies and is being investigated in large and orphan indications like myasthenia gravis (MG), immune thrombocytopenia (ITP) and skin blistering diseases and likely has wider therapeutic potential.
ARGX-117 is a highly differentiated therapeutic antibody equipped with argenx’s proprietary Fc engineering technology NHance® that addresses a novel target in the classic pathway of the complement cascade. With a potentially differentiated mechanism of action, ARGX-117 represents a broad pipeline opportunity across several autoantibody-mediated indications and may have a synergistic effect with lead autoimmune compound ARGX-113.